Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kimberley Franke

Physician Assistant Brownfield, TX Physician Assistant

NPI 1972849834 CMS profile 10754032

706 E Felt St, Brownfield, TX 79316

Open in the dashboard

General payments

$9,674

617 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kimberley Franke of Brownfield, TX is reported in the CMS Open Payments database as having received $9,674 across 617 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,940 114
2024 General $1,748 117
2023 General $1,933 128
2022 General $1,912 110
2021 General $2,142 148

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kimberley Franke
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Kimberley Franke were reported at $1,940. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Kimberley Franke Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,142 $132 $37–$438 $132
2022 $1,912 $155 $48–$522 $149
2023 $1,933 $167 $52–$557 $160
2024 $1,748 $178 $55–$600 $164
2025 $1,940 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $1,228 66 payments
  2. Novo Nordisk Inc $1,064 63 payments
  3. Lilly USA, LLC $881 74 payments
  4. GlaxoSmithKline, LLC. $836 66 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $810 53 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $643 42 payments
  7. AbbVie, Inc. $570 42 payments
  8. Pfizer Inc. $377 26 payments
  9. Amgen Inc. $311 22 payments
  10. Aimmune Therapeutics, Inc. $295 18 payments
  11. Other $2,661 145 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,674 617 payments
Products named General payments · program years 2021–2025
  1. RYBELSUS $946 56 payments
  2. Ozempic $932 55 payments
  3. Kerendia $810 53 payments
  4. FARXIGA $777 41 payments
  5. XIFAXAN $643 42 payments
  6. TRELEGY ELLIPTA $571 45 payments
  7. MOUNJARO $512 44 payments
  8. NURTEC ODT Primary Care $482 26 payments
  9. TRULANCE $453 30 payments
  10. NURTEC ODT Pain $324 23 payments
  11. Other $6,438 431 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 121 drugs

Part D claims

5,134

Median for Physician Assistant: 241

Drug cost

$399,879

Median for Physician Assistant: $4,110

Branded share of claims

21.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 66 $65,219
Farxiga Dapagliflozin Propanediol Brand 86 $56,274
Mounjaro Tirzepatide Brand 32 $33,630
Rexulti Brexpiprazole Brand 20 $28,518
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 27 $24,360
Rybelsus Semaglutide Brand 21 $23,418
Kerendia Finerenone Brand 18 $18,909
Eliquis Apixaban Brand 23 $15,534
Jardiance Empagliflozin Brand 19 $15,192
Januvia Sitagliptin Phosphate Brand 21 $12,641

The 10 drugs with the highest cost, of 121 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $214
$214 18 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $206
$206 86 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $149
$149 — —
ZENPEP
  • AIMMUNE THERAPEUTICS, INC. $115
$115 — —
MOUNJARO
  • Lilly USA, LLC $96
$96 32 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

617 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record